Table 2.

Cox regression analysis of overall survival in patients with hepatocellular carcinoma of different BCLC stages

Variable	BCLC stage 0 (N = 66)		BCLC stage A (N = 865)		BCLC stage B (N = 575)		BCLC stage C (N = 810)
	HR (95 % CI)	P value	HR (95 % CI)	P value	HR (95 % CI)	P value	HR (95 % CI)	P value
Sex
Female	1		1		1		1
Male	0.70 (0.85–1.98)	0.79	0.81 (0.64–1.03)	0.09	0.95 (0.68–1.31)	0.76	0.90 (0.67–1.21)	0.49
Age (years)
< 60	1		1		1		1
≥ 60	0.83 (0.61–1.11)	0.22	0.84 (0.64–1.09)	0.19	0.71 (0.50–1.01)	0.06	0.81 (0.59–1.09)	0.17
Smoking
Yes	1		1		1		1
No	0.52 (0.22–1.23)	0.14	0.59 (0.08–4.41)	0.61	0.89 (0.37–2.20)	0.82	0.81 (0.30–2.19)	0.68
Alcohol use
Yes	1		1		1		1
No	0.70 (0.10–6.25)	0.67	0.75 (0.10–5.59)	0.78	0.82 (0.55–1.22)	0.33	0.52 (0.19–1.42)	0.20
HBV
Negative	1		1		1		1
Positive	0.30 (0.04–1.21)	0.25	0.22 (0.03–1.62)	0.14	0.43 (0.27–0.71)	0.001	0.40 (0.27–0.58)	< 0.001
HCV
Negative	1		1				1
Positive	0.95 (0.73–1.10)	0.49	0.51 (0.07–3.78)	0.51	0.88 (0.66–1.18)	0.41	0.89 (0.41–1.12)	0.35
Cirrhosis
Absent	1		1		1		1
Present	0.60 (0.42–0.72)	0.006	0.55 (0.39–0.78)	0.001	0.91 (0.59–1.40)	0.66	0.87 (0.53–1.43)	0.58
Child-Pugh class
A			1		1		1
B			0.55 (0.43–0.71)	< 0.001	0.41 (0.28–0.61)	< 0.001	0.40 (0.29–0.55)	< 0.001
Tumor size	0.98 (0.97–1.01)	0.238	1.06 (0.94–1.20)	0.289	1.03 (0.92–1.15)	0.609	0.98 (0.96–1.01)	0.238
Tumor number	0.95 (0.96–1.02)	0.058	1.01 (0.83–1.20)	0.971	1.06 (0.91–1.24)	0.391	0.94 (0.94–1.05)	0.052
Treatment
Non-surgery	1		1		1		1
Surgery	2.31 (1.22–4.61)	0.019	1.41 (1.17–1.70)	< 0.001	2.10 (1.56–2.82)	< 0.001	3.10 (2.02–4.70)	< 0.001

BCLC stage: Barcelona clinic liver cancer; HR: Hazard ratio; CI: Conference incidence; HBV: Hepatitis B virus; HCV: Hepatitis C virus